Bone turnover markers (BTMs) have been developed many years ago to study, in combination with imaging techniques, bone remodeling in adults. In children and adolescents, bone metabolism differs from adults since it implies both growth and bone remodeling, suggesting an age- and gender-dependent BTM concentration. Therefore, specific studies have evaluated BTMs in not only physiological but also pathological conditions. However, in pediatrics, the use of BTMs in clinical practice is still limited due to these many children-related specificities. This review will discuss about physiological levels of BTMs as well as their modifications under pathological conditions in children and adolescents. A focus is also given on analytical and clinical challenges that restrain BTM usefulness in pediatrics.
Bone has a very dynamic metabolism with continuous bone formation and resorption processes occurring, at different rates, throughout the entire life. In children and adolescents, bone formation is particularly predominant to respond to skeletal growth . Teenage years are characterized by a progressive increase of sex hormones and the appearance of secondary sexual characteristics leading to a peak of bone mineral density (BMD) at Tanner stage III . Once this achieved, BMD normally remains relatively stable in young adults by maintaining a balance between time- and space-coordinated bone formation and resorption. This equilibrium progressively vanishes with age, and particularly at menopause, to be replaced by a dominant bone resorption process .
Serum markers of bone turnover are designed to reflect the systemic activity of the osteoblast or of the osteoclast system. As these markers originate from the entire skeleton, they reflect the cumulative activity of bone cells from all skeletal locations (e.g., axial skeleton, appendicular skeleton) and from all skeletal compartments (e.g., cortical bone, trabecular bone). Biochemical markers of bone metabolism are, therefore, mostly used to assess systemically active disorders. Nevertheless, local processes, such as fracture healing, can influence systemic bone marker levels if they are sufficiently metabolically active or involve a sufficient amount of bone tissue . While imaging and DXA measurements remain the gold standards to diagnose bone diseases in adults, bone turnover markers (BTMs) have found a place in the follow-up of treatment of diseases such as osteoporosis . For the time being, in pediatrics, BTMs remain mainly research tools [6, 7]. However, there are genetic, chronic, or therapy-induced bone disorders that may require BMD and BTMs measurements. Indeed, disorders that may concern both adults and children such as Paget disease, renal osteodystrophy, or glucocorticoid-induced osteoporosis are requiring a close follow-up .
From a laboratory point of view, a typical bone metabolism investigation is composed of creatinine, calcium, phosphate, parathyroid hormone (PTH), and 25-hydroxy-vitamin D measurements . BTMs such as osteocalcin (OC) or bone alkaline phosphatase (BALP) are considered as different entities kept for specific investigations. BTMs are usually considered as either bone formation or bone resorption markers. They can further be categorized in collagenous or non-collagenous markers (Fig. 1). Noticeably, age, gender, and ethnicity are major peak BMD determinants, and by extension of BTMs. Historically, most of BTMs measurements were developed in urine samples . However, blood samples being easier to handle and facing less pre-analytical variations, serum, or plasma BTMs are now preferred in laboratory medicine .
Initially developed to study adult bone diseases such as osteoporosis, BTM measurement in children faces additional challenges, the establishment of pediatric reference values being an important one. Indeed, the establishment of proper reference ranges requires to handle very large cohorts [10, 11]. Besides the difficulty of recruiting large cohorts of children, the ethical issue of blood collection in very young infants and toddlers for research purposes should not be underestimated . Finally, because reference values are assay dependent, these studies need to be regularly up-dated to fit with the new laboratory devices .
Since definition of relevant blood biomarkers includes adequate reference ranges, a PRISMA approach was performed to search for articles providing pediatric reference ranges for BTMs. Pubmed and Embase databases were searched using “children or adolescent”; “bone turnover markers”; and “reference ranges” as terms. We found 181 records from which 82 were directly removed being either duplicates, published in languages other than English or non-research articles. Out of the 99 remaining records, 84 were excluded based on the following criteria “cohort of unhealthy individuals,” “cohorts too small (< 120 individuals),” “inappropriate age of the cohort,” “urine samples,” “insufficiently described method,” “inappropriate calculation of reference ranges.” Table 1 summarizes the pediatric reference ranges reported in the 15 accepted articles. This review will discuss on blood biomarkers identified using this approach. The first part will focus on the expression profile of each BTM and their physiological variations and the second part their variations in pathological conditions.
Bone Turnover Markers: Physiological Insights and Measurement
Procollagen Type I N-Propeptide (PINP)
Procollagen type I-N-propeptide (PINP) is a 35 kDa bone formation marker. PINP is cleaved from extracellular matrix procollagen type I molecules secreted by osteoblasts before their assembly into organized fibers. Procollagen type I-C-propeptide (PICP), is its C-terminal counterpart. Although both show similar physio-pathological characteristics, PINP has taken the lead in the field. Indeed, as no automated method have been developed for PICP, PINP has been defined as the preferred bone formation marker for the follow-up of postmenopausal women by the National Bone Alliance in collaboration with the American Association for Clinical Chemistry and by the IFCC-IOF joint Committee for Bone Markers (C-BM) [14, 15]. These PINP automated methods have recently been shown to provide harmonized results [16, 17].
Several studies have established pediatric reference intervals for PINP [2, 18,19,20,21] but data on PICP are much more scarce . In spite of this, studies demonstrate a nonlinear relationship between age and PINP or PICP concentrations (Fig. 1). From birth until 3–4 years, PINP concentration decreases. It then stabilizes or slightly increases until the mid-puberty where it starts a new decrease. There are several links between puberty and PINP levels. First, PINP pubertal peak is earlier in girls than in boys, in line with the earlier onset of puberty for girls . Second, PINP pubertal peak matches with the II/III Tanner stages of breast development in girls and the III Tanner stage of genital development in boys . Finally, correlation has been made between PINP levels, testosterone, and Ghrelin concentration in boys .
Whether there is an association between PINP and growth velocity or bone mineral content (BMC) is still under debate. PINP was correlated to leg growth velocity in very low-birth-weight infants  but studies in older healthy children are lacking. Regarding BMC, Van Coeverden and colleagues showed a PINP direct correlation with BMC at four different sites in boys but not in girls . Still, a correlation between low bone mineral density (BMD), PINP, and amenorrhea was observed in adolescent athlete girls . More recently, Zürcher and colleagues showed that, although PINP was correlated with BMC, it explained a small percentage (Pearson coefficient varying from 0.13 to 0.24 depending of the anatomical site) of bone mineral changes .
PINP is present in serum either as a trimer (“intact”) or as a monomer. Assays that detect only the trimeric form are called intact assays (e.g., IDS intact PINP) whereas assays that detect both monomeric and trimeric forms are defined as total assays (e.g., Roche P1NP assay). The monomeric form is cleared by the kidneys and the trimeric forms by the hepatic endothelium, it follows that liver or kidney diseases will impact the interpretation of the results depending on the type of assay . Hence, in patients suffering from chronic-kidney diseases, PINP concentrations will be particularly overestimated when measured with the total assay . Procedures to limit pre-analytical impacts on PINP measurement state a limited impact of fasting and circadian rhythm-related blood procurement .
Total Alkaline Phosphatase (ALP) and Bone-Specific Alkaline Phosphatase (BALP)
Total alkaline phosphatase (ALP) combines four isoforms: the placental, the germ cell, the intestinal, and the tissue-nonspecific isoforms (expressed in liver, bone, and kidney) . Bone-specific alkaline phosphatase (BALP) differs from the kidney and the liver isoforms by post-translational modifications. BALP, itself, can be further categorized in more isoforms (sometimes called B/I, B1, B1x, and B2) [32, 33]. As ALP combines all these isoforms its specificity to bone diseases is relatively limited. Therefore, total alkaline phosphatase is not recommended for the management of postmenopausal osteoporosis . However, in children, given the low prevalence of hepatic diseases, its use has been recommended by the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA .
BALP, as its name suggests, is an enzyme active at alkaline pH that participates to the growth of hydroxyapatite crystals through the hydrolysis of pyridoxal phosphate (an inhibitor of the hydroxyapatite formation) . BALP is also responsible for the inactivation of the calcification inhibitor osteopontin . BALP is released in the blood stream after disruption of its membrane anchorage to the osteoblasts . Thus, BALP activity is increased in physiological or pathological processes that involve high osteoblastic activity . Therefore, it is commonly accepted as a non-collagenous biomarker of bone formation.
ALP and BALP concentrations during childhood and puberty show the same trends as PINP concentration with a valley during childhood and a peak at beginning/mid-puberty (Fig. 1) [20, 22, 36,37,38,39]. As data are scarce in infants, the contribution of the placental isoform to the level of ALP in the 0–1 year olds is unclear. Although ALP and BALP values are the same for both genders during infancy, pubertal peak is higher and occurs later in boys [38, 39]. Thus, ALP and BALP concentrations are clearly age-related although BALP, on its own, is not a good age predictor in boys . Noticeably, cases of transient hyperphosphatasemia have been reported in infants under 5 years old [41, 42]. In these cases, ALP including BALP and liver isoforms is transiently increased but return to normal after a few weeks without any symptoms.
As PINP, BALP is also tightly associated with height gain velocity . Still, the proportion of BALP isoforms identified by HPLC varies during puberty  suggesting a different impact of each isoforms in matrix mineralization.
Bone metabolism can be modulated during childhood by environmental and anthropometric factors [44,45,46,47]. Notably, weight-loss interventions have shown modifications in BALP activity associated with modified BMD . Because Body Mass Index (BMI) and Vitamin D are tightly linked, the question of an association between BALP concentration and Vitamin D has also emerged. Yet, the existence of an association between BALP concentration and Vitamin D remains unclear. Indeed, many interventional studies have BMD as outcome rather than bone biomarkers , and observational studies based on specific diet have shown contradicting results. For example, two studies conducted by the same group 7 years apart, reported decreased BALP in vegetarian children and increased BALP activity in children with cow’s milk allergy, both groups with deficits in nutritional calcium and vitamin D intakes [49, 50]. A Danish study conducted in adults showed higher BALP and PINP concentrations in vegans compared to omnivore but no differences in β-CTX and osteocalcin (OC) .
From an analytical point of view, ALP is most frequently measured through enzymatic assay based on the hydrolysis of para-nitrophenyl phosphate. This method based on chemical properties of ALP is not isoform specific. Regarding BALP, there are three kinds of BALP assays. (1) Pure enzymatic assays that measure the activity of the enzyme (e.g., Quidel Microvue), (2) immunoassays that measure the mass of the enzyme (e.g., Diasorin Liaison Ostase) and (3) assays that measure activity of the enzyme but provide results in mass units after calibration (e.g., IDS iSYS and Beckman-Coulter Access Ostase) . In addition, high-performance liquid chromatography (HPLC) is sometimes used to investigate specifically BALP isoforms . Because of the high homology between tissue nonspecific isoforms, current immunoassays exhibit different degrees of cross-reactivity with liver alkaline phosphatase . Thus, caution is needed when interpreting results from patients with severe hepatic diseases. Yet, as BALP is almost not influenced by the renal function, BALP was defined as the biomarker of choice in hemodialyzed patient . From a pre-analytical point of view, fasting or circadian rhythm does not impact blood BALP values .
Osteocalcin, also called bone Gla protein, is a 49 kDa protein secreted by osteoblasts into the bone matrix where it is bound to the hydroxyapatite crystals through its three γ-carboxyglutamate residues. The carboxylation of these three glutamate residues is Vitamin K-dependent and is modulated by anti-Vitamin K drugs (e.g., warfarin) . The fraction of OC that enters the blood circulation is dependent on the OC carboxylation levels. In the circulation, the uncarboxylated form of OC has a role in glucose metabolism . Still, because secreted OC correlates to histomorphometric bone formation measurements , OC is generally considered as a non-collagenous bone formation marker. Yet, caution must be exercised since a fraction of bone matrix-bound OC can be released by osteoclasts during bone resorption, impact of which is still controversial .
Data regarding OC expression profiles vary in the literature. While some found it quite stable , other have shown that OC is elevated during infancy, decreases during childhood before reaching a peak at early puberty [2, 20, 21] (Fig. 1). Contrary to PINP and BALP that have the same values for boys and girls during childhood, OC levels may be slightly lower in boys during that period. Moreover, the ratio between the uncarboxylated and the carboxylated OC forms is also increased in children compared to adults . Given the role of the uncarboxylated form of OC in glucose metabolism, the clinical significance of an elevated ratio in children remains controversial and might only be due to a distinct bone/glucose homeostasis during childhood. In adults, this ratio is usually admitted to reflect Vitamin K bone status and suggest that individuals with higher levels of uncarboxylated OC might be Vitamin K deficient . While a meta-analysis has shown an inverse relationship between Vitamin K1 intakes and risk of fractures , interventional studies with Vitamin K supplementation show conflicting results .
Still, because OC is implicated in glucose metabolism, several studies focused on its expression in overweight individuals. OC tends to be diminished in overweight postmenopausal women and elderly men [64,65,66,67]. In children, BMI and homeostasis model assessment of insulin resistance (HOMA-IR) were found to be independent predictors of serum OC concentration together with age . Also, in children, an OC concentration < 44.5 ng/ml was reported to be a good predictor of the progression of non-alcoholic steatosis, a disease typically linked to obesity . Of note, children with glucocorticoid-induced osteoporosis show lower OC concentration . However, whether this decrease depends on the action of glucocorticoids on glucose metabolism or on bone homeostasis remains unclear.
From an analytical point of view, OC is an unstable protein. To circumvent this problem, standardized pre-analytical settings are recommended . In addition, the C-terminal sequence of OC being the least stable, immunoassays targeting the NH2-terminal mid-fragment (N-mid OC) are definitively preferred  and are now commonly used in routine. Furthermore, this more stable fragment accumulates less in uremic samples compared to the entire protein [71, 72].
Pyridinoline- and deoxypyrydinoline-Cross-linked telopeptides are bone resorption markers derived from the type I collagen that represents more than 90% of the bone matrix collagen. These telopeptides are classified as NTXs or CTXs depending whether they derive from the N- or C-terminal end. While CTXs are released from collagen through cathepsin K-mediated cleavage, the C-terminal cross-linked telopeptides of type I collagen (ICTP) are derived from metalloproteinase digestion . Since the original radioimmunoassay developed for ICTP  has never been automated, its usefulness in routine laboratories is limited and recent pediatric studies are scarce. Therefore, nowadays, assays that measure CTXs, regardless of the isomers are grouped under the generic name of CrossLaps and are considered as the reference resorption biomarker for osteoporosis in postmenopausal women [14, 15]. The most currently used automated assays have antibodies against β-CTX epitopes. As reported by Chubb et al. , there is significant disagreement and limited commutability between the different methods, impeding their value as a clinical tool. The IFCC-IOF Committee for Bone Metabolism recently reinforced these observations and, in addition, showed substantial within- and between-assay variation, concluding that harmonization is a must .
In terms of development, CTX expression profile during childhood differs from PINP and ICTP, not showing a peak in early infancy. During childhood, CTX expression is relatively stable, slightly increasing to reach a peak at early puberty followed by a decrease [18, 20, 21, 36, 77] (Fig. 1).
Several possible determinants of CTX levels have been assessed. First, β-CTX is independently associated with age and height in children [14, 28, 67]. This is also the case for girls with central precocious puberty . Yet, contrarily to PINP, no association with BMC or DXA measurements was found [27, 79]. Vitamin D is another possible determinant as a season-related inverse relationship between serum 25-hydroxyvitamin D (25(OH)D) and CTX concentrations has been observed after adjustment for several confounding factors . Interventional studies have also confirmed this association by showing that Vitamin D supplementation could decrease both PINP and CTX levels in Indian Vitamin D-deficient children . Finally, the link between CTX and BMI has also been evaluated with contradicting data. While some show positive association [82, 83], others show no or negative association between CTX and BMI [18, 21, 84].
From a pre-analytical point of view, CTX expression is more influenced by fasting, circadian rhythm, and renal failure than PINP . Thus, a fasting morning blood collection is strongly recommend .
Tartrate Resistant Acid Phosphatase (TRAP)
TRAP, measured 40 years ago in osteoclasts , is an enzyme secreted not only by differentiating osteoclasts but also by other cells from the monocyte-macrophage lineage. Of the two TRAP isoforms (5a and dimer 5b), the second, located at the ruffled border, is the osteoclast specific one . In vitro, TRAP-5b activity correlating with the number of osteoclasts , with CTX-I in vivo and In vitro  and with BMD [87, 90], is considered a good bone resorption marker. Of clinical interest, being insensitive to kidney function [91, 92], TRAP-5b serum concentrations correlate with the number of osteoclasts and bone formation rate not only in patients with normal kidney function but also in uremic patients .
At the present time, despite considerable efforts, pediatric data in population-representative samples are sorely lacking. There are, however, few articles reporting TRAP-5b pediatric reference ranges [36, 38, 94] that set the scene. Positive correlation with BALP activity and its gender-dependent concentrations in two studies [28, 30] provides additional support for its role as a valid biomarker. Compared to other BTMs, TRAP-5b has a very specific expression profile in children with the highest values at birth followed by a constant decline that accelerates at puberty . Although Chen et al.  observed a possible peak at early puberty, this was not confirmed by other studies.
Lau et al.  and later Scarnecchia et al.  evaluated more than 30 years ago the potential of serum TRAP measured spectrophotometrically as a marker of bone resorption. Since then major methodological improvements have been brought. Today, assays based on immune-immobilization capturing both isoforms, or singly TRAP-5b, followed by enzyme activity assessment are available [89, 97, 98]. TRAP-5b can be measured with an automated method (IDS iSYS) and a manual EIA (Nittobo Medical), both methods showing a good agreement .
Interpretation of Bone Marker Results
The interpretation of serum bone marker levels in children is more complex than in adults. Indeed, in adults, osteoblasts and osteoclasts are mostly dedicated to bone remodeling  while in children, bone cells are also participating in bone growth, which involves processes other than remodeling, such as endochondral ossification and cortical bone modeling . Bone markers in children, therefore, correlate with height velocity, as has already been noted more than 70 years ago for total ALP  and for other bone markers that have been developed thereafter.
As bone markers in children reflect the cumulative effect of growth and remodeling processes, they may not be as accurate as expected in assessing the bone remodeling activity. One such instance occurs upon accelerated remodeling coupled to slow growth as sometimes observed in severe forms of osteogenesis imperfecta (OI). Children with severe OI have markedly increased bone remodeling activity, as demonstrated by static and dynamic iliac bone histomorphometry, a technique that evaluates bone remodeling independent of bone growth in length [102, 103]. In this situation, despite increased remodeling, serum bone marker concentrations are typically normal or low , a discrepancy that may partially be explained by the slower growth of these children .
Apart from skeletal growth, systemic bone cell activity in children is influenced by a myriad of other factors, many yet unknown, which may influence bone marker results. However, a few key factors are particularly relevant for the clinician interpreting bone marker results. In many situations, parathyroid hormone (PTH) plays an important role, as PTH directly stimulates bone remodeling activity and PTH serum concentrations vary with vitamin D status . Another consideration is the effect of immobilization. Bed-rest studies have shown that in healthy people, bone resorption markers increase within 24 to 48 h after immobilization [107, 108]. Acute or chronic lack of physical activity is frequent in children who are undergoing bone health assessments and, therefore, may influence bone marker results. Finally, bone marker levels can be influenced by drug therapies, as discussed in the following section.
Drug Effects on Bone Markers
High-dose glucocorticoids are used to treat a wide variety of disorders and have adverse effects on the skeleton, such as suppression of longitudinal growth, osteoblast activity, and bone turnover [109, 110]. These effects are consistently observed across a wide range of clinical situations. Bone formation markers decreased within 24 to 48 h after intravenous prednisolone injections in children with asthma . Dexamethasone treatment in preterm infants, to manage the development of chronic lung disease, and led to a marked suppression of bone formation and bone resorption markers within 24 h after the first dose . In another study on preterm infants with bronchopulmonary dysplasia, dexamethasone at a daily dose of 500 µg/kg led to a marked decrease in bone formation and bone resorption markers within three days of starting treatment . In children and adolescents with inflammatory bowel disease, glucocorticoid treatment led to reduction in bone turnover markers . In a study on 24 boys with Duchenne muscular dystrophy treated with glucocorticoids, serum levels of bone formation (PINP, BALP, osteocalcin) and bone resorption (CTX, TRAP-5b) were all decreased . Thus, high-dose systemic glucocorticoid treatment consistently decreases bone marker levels.
The effect of inhaled glucocorticoids on bone development is more subtle than that of systemic glucocorticoids but still detectable by biochemical bone markers. A cross-sectional study of bone markers found that children with asthma had lower bone formation markers when they received inhaled glucocorticoids . One month of treatment with 200 µg of inhaled budesonide (a corticosteroid analog) per day resulted in significantly decreased levels of bone formation and resorption markers .
In contrast to glucocorticoids, bone is usually the intended target of bisphosphonate therapy. These drugs inactivate osteoclasts and thereby decrease bone resorption and increase bone mass . Bisphosphonates are widely used in children who suffer from bone fragility disorders such as OI. Consistent with the mechanism of action, intravenous infusions with the bisphosphonate Pamidronate lead, almost immediately, to a marked decrease in bone resorption activity . A more gradual decline in bone resorption markers was observed when children with OI were treated with oral Alendronate . The bone resorption marker CTX remains low in children and adolescents with OI even after many years of bisphosphonates therapy , reflecting persistent bone resorption long after discontinuation of bisphosphonate treatment .
Apart from bisphosphonates, bone resorption can also be targeted with denosumab, a drug that uses RANKL antibodies to inhibit osteoclasts. While bisphosphonates lead to long-term suppression of bone resorption, RANKL antibody treatment has a more transient effect . A recent example of the use of bone markers in pediatric settings is the detection of the ‘rebound’ phenomenon in children treated with RANKL antibody. It was observed that the effect of an injection with RANKL antibody on bone resorption markers persistent for a much shorter duration in children than what had previously been seen in adults receiving the same treatment . Eventually it was found that this rapid rebound in bone resorption was associated with hypercalciuria and, in some patients, hypercalcemia [125, 126]. Thus, the bone markers can be helpful to monitor treatment effects of drugs that have an effect on bone metabolism.
Many studies have examined markers of bone turnover in growth hormone deficient children. In untreated patients, bone formation and bone resorption marker levels are lower than in healthy controls [127, 128]. Once growth hormone treatment is started, levels of all markers of bone metabolism rise within a few weeks [127,128,129,130,131] and bone marker changes often correlate with the longer-term growth response [127, 129, 130, 132]. Similar observations have been made in short children without growth hormone deficiency who received growth hormone [129, 130, 133,134,135]. Given the correlation between height velocity and bone marker levels, many authors during the past three decades have suggested that bone markers can be used to predict the response to growth hormone treatment [56, 127,128,129,130,131]. However, the use of bone markers for growth prediction models has not been widely adopted in clinical practice, presumably because of a cost/effectiveness perspective, of the somewhat cumbersome approach and of the insufficient accuracy for clinical decision making .
Vitamin D Deficiency and Vitamin D Deficiency Rickets
A study on 468 vitamin D-deficient (serum 25-OH vitamin D < 50 nmol/l) school children in India revealed that a 6-month supplementation with vitamin D was associated with decreasing serum PINP and CTX levels . These children had initially elevated serum PTH concentrations but they did not have rickets. As PTH stimulates bone turnover, it is expected that the correction of secondary hyperparathyroidism by vitamin D supplementation leads to a decrease in bone makers. Accordingly, the study found that the decrease in PINP and CTX serum concentrations depended on the baseline serum level of PTH.
The time course of bone markers after vitamin D supplementation is different when vitamin D deficiency is sufficiently severe to cause rickets. In that situation, vitamin D supplementation leads to an initial increase in bone turnover markers for a few weeks, followed by an eventual decline . However, it is not clear that determining markers of bone metabolism beyond total ALP is of clinical use in the context of vitamin D deficiency rickets. As the contribution of the liver isoform to total ALP activity is small in children with increased bone turnover, the determination of bone-specific ALP does not offer a clear advantage in rickets .
Secondary Bone Disease in Chronic Disorders
Many serious diseases in children associated with slow skeletal growth have an inflammatory component, or are associated with immobilization. These factors tend to decrease bone formation, but they may have different effects on bone resorption. Slow growth is expected to decrease bone resorption, whereas inflammation and acute immobilization often lead to transient increases in bone resorption . The following provides some examples of studies that have used bone markers in the context of secondary bone disease in children.
Low bone formation markers have been observed in disease states as diverse as malnutrition, phenylketonuria, cholestatic liver disease, active rheumatic diseases, and severe burns [139,140,141,142,143,144,145]. Bone formation markers also reflected the acceleration of bone metabolism during the successful therapy of these disorders [140, 142, 146]. A 2-year longitudinal study on bone development in 220 children living with HIV and receiving antiretroviral therapy found persistently lower bone turnover markers PINP, CTX, OC than in age- and sex-matched controls, even though height velocity was similar in the two groups , suggesting that low bone turnover was caused either by the ongoing infection or the drug therapy.
One of the chronic childhood conditions where bone involvement has been studied in some detail is inflammatory bowel disease . Untreated inflammatory bowel disease is characterized by low bone turnover, as can be observed both in biochemical bone markers and in iliac bone histomorphometry analyses [114, 149, 150]. Effective treatment can quickly reverse these disease effects, as shown in a study on 103 children Crohn’s disease, where 10 weeks of treatment with infliximab led to a marked increase in serum levels of BALP, PINP and CTX .
The time course of bone metabolism in acute lymphoblastic leukemia is somewhat similar to Crohn’s disease. Several studies found that in newly diagnosed children, bone turnover markers were very low and decreased further with treatment regimens that included high doses of glucocorticoids [145, 152, 153]. After glucocorticoids were discontinued, bone markers levels increased. Similar phases of decrease and recovery of markers occurred during intensification cycles that included corticosteroids . In the long run, survivors of childhood leukemia seem to have normal bone metabolism. A study on 251 individuals who had been cured of leukemia an average of 13 years before did not show abnormalities in bone turnover markers .
Chronic-kidney disease in children is often associated with slow growth and impaired bone mineralization as well as abnormalities of calcium, phosphorus, PTH, fibroblast growth factor 23, and vitamin D metabolism, a constellation of features that is termed chronic-kidney disease—mineral and bone disorder . CTX and OC are not particularly useful markers of bone metabolism in this context, as these markers are cleared by the kidneys and, therefore, are inevitably increased when renal clearance is reduced . A cross-sectional study in 63 children with chronic-kidney disease found that PINP and BALP are correlated with serum levels of tumor necrosis factor alpha . One 5-year prospective study in 15 children with chronic-kidney disease found mildly elevated total ALP and PINP levels in a subgroup of patients and normal TRAP-5b results throughout the study period in all patients . Kidney transplantation had no consistent effect on PINP and TRAP-5b levels . Given the paucity of information on markers of bone turnover in the context of chronic-kidney disease in children, total ALP activity remains the marker of bone turnover that is currently recommended for clinical use .
During the past three decades, biochemical markers of bone turnover have helped in the characterization of bone disorders in children and in the assessment of the effects of drug therapies that target bone or have adverse effects on bone. However, many questions remain opened, and it is still unclear whether BTMs could help identifying children at risk of fracture or could be used in the follow-up of bone therapies in children. As such, Despite being important tools in the context of research in the area of pediatric bone disorders, their utility in clinical pediatric practice is not yet well established. Consequently, the clinical use of bone markers is currently mostly limited to highly specialized centers. Indeed in pediatric metabolic bone disorders, such as rickets and mineral and bone disorder of chronic-kidney disease, serum total ALP still is the parameter of choice for an informed clinical management. Conversely, in young adults, a flow chart for determining causes of bone fragility that includes BTMs has been proposed .
Several gaps have yet to be filled to improve the interpretation of BTMs concentration. One is the establishment of population-driven pediatric reference ranges. This requires multi-centric international endeavors. As Tahamasebi et al.  have stated “the use of inappropriate reference intervals impacts clinical decision making and is potentially detrimental on the quality of patient healthcare.” This statement holds for BTMs for which in addition, measurements, harmonization is imperative, a task that the IFCC C-BM is currently tackling . Another approach in using BTMs is the recently proposed “Bone Turnover Index” based on the calculation of z-scores . This statistical tool could provide additional information on the trajectory of bone metabolism. It, however, requires the establishment of proper age-, gender-, and ethnicity-matched reference values as mentioned above.
Tuchman S, Thayu M, Shults J et al (2008) Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 153:484–490. https://doi.org/10.1016/j.jpeds.2008.04.028
Bayer M (2014) Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0–18 years. Osteoporos Int 25:729–736. https://doi.org/10.1007/s00198-013-2485-4
Eastell R, Szulc P (2017) Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol 5:908–923
Ivaska KK, Gerdhem P, Åkesson K et al (2007) Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. https://doi.org/10.1359/jbmr.070505
Camacho PM, Petak SM, Binkley N et al (2016) American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-executive summary. Endocr Pract 22:1–42. https://doi.org/10.4158/EP161435.ESGL
Bakkaloglu SA, Bacchetta J, Lalayiannis AD et al (2021) Bone evaluation in paediatric chronic kidney disease: clinical practice points from the european society for paediatric nephrology CKD-MBD and dialysis working groups and CKD-MBD working group of the ERA-EDTA. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa210
Simm PJ, Biggin A, Zacharin MR et al (2018) Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 54:223–233
Eapen E, Grey V, Don-Wauchope A, Atkinson SA (2008) Bone health in childhood: usefulness of biochemical biomarkers. EJIFCC 123–135
Jürimäe J (2010) Interpretation and application of bone turnover markers in children and adolescents. Curr Opin Pediatr 22(4):494–500
Tahmasebi H, Higgins V, Fung AWS, et al (2017) Pediatric reference intervals for biochemical markers: gaps and challenges, recent national initiatives and future perspectives. eJIFCC 82:43–63
Rustad P, Felding P, Lahti A (2004) Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma. Clin Chem Lab Med 42:783–791. https://doi.org/10.1515/CCLM.2004.131
Karbasy K, Ariadne P, Gaglione S et al (2014) Advances in pediatric reference intervals for biochemical markers: establishment of the caliper database in healthy children and adolescents/Napredak U Oblasti Pedijatrijskih Referentnih Intervala Za Biohemijske Markere: Izrada Baze Podataka Caliper Kod Z. J Med Biochem 34:23–30. https://doi.org/10.2478/jomb-2014-0063
Estey MP, Cohen AH, Colantonio DA et al (2013) CLSI-based transference of the CALIPER database of pediatric reference intervals from abbott to beckman, ortho, roche and siemens clinical chemistry assays: direct validation using reference samples from the CALIPER cohort. Clin Biochem 46:1197–1219. https://doi.org/10.1016/j.clinbiochem.2013.04.001
Bauer D, Krege J, Lane N et al (2012) National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. https://doi.org/10.1007/s00198-012-2049-z
Vasikaran S, Cooper C, Eastell R et al (2011) International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med. https://doi.org/10.1515/CCLM.2011.602
Cavalier E, Eastell R, Rye Jørgensen N et al (2019) A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type i procollagen (PINP): a report from the IFCC-IOF joint committee for bone metabolism. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2019-0174
Vasikaran SD, Bhattoa HP, Eastell R et al (2020) Harmonization of commercial assays for PINP; the way forward. Osteoporos Int. https://doi.org/10.1007/s00198-020-05310-6
Huang Y, Eapen E, Steele S, Grey V (2011) Establishment of reference intervals for bone markers in children and adolescents. Clin Biochem 44:771–778. https://doi.org/10.1016/j.clinbiochem.2011.04.008
Morovat A, Catchpole A, Meurisse A et al (2013) IDS iSYS automated intact procollagen-1-Nterminus pro-peptide assay: Method evaluation and reference intervals in adults and children. Clin Chem Lab Med 51:2009–2018. https://doi.org/10.1515/cclm-2012-0531
Diemar SS, Lylloff L, Rønne MS et al (2021) Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (β-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatas. Bone 146:115879. https://doi.org/10.1016/j.bone.2021.115879
Geserick M, Vogel M, Eckelt F et al (2020) Children and adolescents with obesity have reduced serum bone turnover markers and 25-hydroxyvitamin D but increased parathyroid hormone concentrations – Results derived from new pediatric reference ranges. Bone. https://doi.org/10.1016/j.bone.2019.115124
Van Der Sluis IM, Hop WC, Van Leeuwen JPTM et al (2002) A cross-sectional study on biochemical parameters of bone turnover and vitamin D metabolites in healthy dutch children and young adults. Horm Res. https://doi.org/10.1159/000058378
Jürimäe J, Pomerants T, Tillmann V, Jürimäe T (2009) Bone metabolism markers and ghrelin in boys at different stages of sexual maturity. Acta Paediatr Int J Paediatr 98:892–896. https://doi.org/10.1111/j.1651-2227.2008.01193.x
Kajantie E, Dunkel L, Risteli J et al (2001) Markers of type I and III collagen turnover as indicators of growth velocity in very low birth weight infants. J Clin Endocrinol Metab 86:4299–4306. https://doi.org/10.1210/jcem.86.9.7869
Van Coeverden SCCM, Netelenbos JC, De Ridder CM et al (2002) Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol 57:107–116. https://doi.org/10.1046/j.1365-2265.2002.01573.x
Christo K, Prabhakaran R, Lamparello B et al (2008) Bone metabolism in adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics 121:1127–1136. https://doi.org/10.1542/peds.2007-2392
Zürcher SJ, Borter N, Kränzlin M et al (2020) Relationship between bone mineral content and bone turnover markers, sex hormones and calciotropic hormones in pre- and early pubertal children. Osteoporos Int 31:335–349. https://doi.org/10.1007/s00198-019-05180-7
Koivula MK, Ruotsalainen V, Björkman M et al (2010) Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem 47:67–71. https://doi.org/10.1258/acb.2009.009110
Cavalier E, Lukas P, Carlisi A, et al (2013) Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: The assay matters. Clin Chim Acta 425
Szulc P, Naylor K, Hoyle NR et al (2017) Use of CTX-I and PINP as bone turnover markers: national bone health alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int 28:2541–2556. https://doi.org/10.1007/s00198-017-4082-4
Nizet A, Cavalier E, Stenvinkel P et al (2020) Bone alkaline phosphatase: an important biomarker in chronic kidney disease—mineral and bone disorder. Clin Chim Acta 501:198–206. https://doi.org/10.1016/j.cca.2019.11.012
Haarhaus M, Monier-Faugere MC, Magnusson P, Malluche HH (2015) Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2015.02.323
Haarhaus M, Fernström A, Magnusson M, Magnusson P (2009) Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfp300
Lomashvili KA, Cobbs S, Hennigar RA et al (2004) Phosphate-induced vascular calcification: Role of pyrophosphate and osteopontin. J Am Soc Nephrol 15:1392–1401. https://doi.org/10.1097/01.ASN.0000128955.83129.9C
Van Hoof VO, De Broe ME (1994) Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci 31:197–293. https://doi.org/10.3109/10408369409084677
Rauchenzauner M, Schmid A, Heinz-Erian P et al (2007) Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92:443–449. https://doi.org/10.1210/jc.2006-1706
Ladang A, Rousselle O, Huyghebaert L et al (2020) Parathormone, bone alkaline phosphatase and 25-hydroxyvitamin D status in a large cohort of 1200 children and teenagers. Acta Clin Belgica Int J Clin Lab Med 22:1–6. https://doi.org/10.1080/17843286.2020.1769285
Fischer DC, Mischek A, Wolf S et al (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49:546–553. https://doi.org/10.1258/acb.2012.011274
Colantonio DA, Kyriakopoulou L, Chan MK et al (2012) Closing the gaps in pediatric laboratory reference intervals: a caliper database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem 58:854–868. https://doi.org/10.1373/clinchem.2011.177741
Topal İ, Gümüş B (2020) Can bone-specific alkaline phosphatase and osteocalcine levels be used to determine the age in children? Am J Forensic Med Pathol 41:182–187. https://doi.org/10.1097/PAF.0000000000000555
Oladipo OO, DeCrescenzo AJ, Marquez CP, Okorodudu AO (2017) Increased alkaline phosphatase in a child. Clin Chem 63(6):1174–1175
Otero JL, González-Peralta RP, Andres JM et al (2011) Elevated alkaline phosphatase in children: an algorithm to determine when a “Wait and See” approach is optimal. Clin Med Insights Pediatr 5:15–18. https://doi.org/10.4137/cmped.s6872
Magnusson P, Häger A, Larsson L (1995) Serumosteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 38:955–960. https://doi.org/10.1203/00006450-199512000-00021
Chaplais E, Thivel D, Greene D et al (2015) Bone-adiposity cross-talk: implications for pediatric obesity: a narrative review of literature. J Bone Miner Metab 33:592–602. https://doi.org/10.1007/s00774-015-0654-6
Gajewska J, Ambroszkiewicz J, Klemarczyk W et al (2018) The effect of weight loss on body composition, serum bone markers, and adipokines in prepubertal obese children after 1-year intervention. Endocr Res 43:80–89. https://doi.org/10.1080/07435800.2017.1403444
Rizzoli R (2021) Dairy products and bone health. Aging Clin Exp Res. https://doi.org/10.1007/s40520-021-01970-4
Landry BW, Driscoll SW (2012) Physical activity in children and adolescents. PM R 4:826–832. https://doi.org/10.1016/j.pmrj.2012.09.585
Gajewska J, Weker H, Ambroszkiewicz J et al (2013) Alterations in markers of bone metabolism and adipokines following a 3-month lifestyle intervention induced weight loss in obese prepubertal children. Exp Clin Endocrinol Diabetes 121:498–504. https://doi.org/10.1055/s-0033-1347198
Ambroszkiewicz J, Rowicka G, Chelchowska M et al (2014) Biochemical markers of bone metabolism in children with cow’s milk allergy. Arch Med Sci 10:1135–1141. https://doi.org/10.5114/aoms.2013.36906
Ambroszkiewicz J, Klemarczyk W, Gajewska J et al (2007) Serum concentration of biochemical bone turnover markers in vegetarian children. Adv Med Sci 52:279–282
Hansen L, Tjønneland A, Køster B et al (2018) Vitamin D status and seasonal variation among danish children and adults: a descriptive study. Nutrients. https://doi.org/10.3390/nu10111801
Cavalier E, Souberbielle JC, Gadisseur R et al (2014) Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 47:1227–1230. https://doi.org/10.1016/j.clinbiochem.2014.04.007
Magnusson P, Löfman O, Larsson L (1992) Determination of alkaline phosphatase isoenzymes in serum by high-performance liquid chromatography with post-column reaction detection. J Chromatogr B Biomed Sci Appl 576:79–86. https://doi.org/10.1016/0378-4347(92)80177-R
Greenblatt MB, Tsai JN, Wein MN (2017) Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin Chem 62(2):464–474
Cavalier E, Delanaye P, Collette J et al (2006) Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 371:107–111. https://doi.org/10.1016/j.cca.2006.02.029
Tobiume H, Kanzaki S, Hida S et al (1997) Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab 82:2056–2061. https://doi.org/10.1210/jc.82.7.2056
Koshihara Y, Hoshi K (1997) Vitamin K(2) enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 12:431–438. https://doi.org/10.1359/jbmr.1922.214.171.1241
Lee NK, Sowa H, Hinoi E et al (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469. https://doi.org/10.1016/j.cell.2007.05.047
Delmas PD, Demiaux B, Malaval L et al (1986) Serum bone gamma carboxyglutamic acid-containing protein in primary hyperparathyroidism and in malignant hypercalcemia. Comparison with bone histomorphometry. J Clin Invest 77:985–991. https://doi.org/10.1172/JCI112400
Van Summeren M, Braam L, Noirt F et al (2007) Pronounced elevation of undercarboxylated osteocalcin in healthy children. Pediatr Res 61:366–370. https://doi.org/10.1203/pdr.0b013e318030d0b1
Sokoll LJ, Sadowski JA (1996) Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr 63:566–573. https://doi.org/10.1093/ajcn/63.4.566
Hao G, Zhang B, Gu M, Chen C, Zhang Q, Zhang G, Cao XM (2017) Vitamin K intake and the risk of fractures A meta-analysis. Medicine 96:e6725
Rodríguez-Olleros Rodríguez C, Díaz Curiel M (2019) Vitamin K and bone health: a review on the effects of vitamin K deficiency and supplementation and the effect of non-vitamin K antagonist oral anticoagulants on different bone parameters. J Osteoporos 20691476
Szulc P, Seeman E, Delmas PD (2000) Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 11:281–294
Im JA, Yu BP, Jeon JY, Kim SH (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396:66–69. https://doi.org/10.1016/j.cca.2008.07.001
Kindblom JM, Ohlsson C, Ljunggren O et al (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24:785–791. https://doi.org/10.1359/jbmr.081234
Bin OhS, Lee WY, Nam HK et al (2019) Serum osteocalcin levels in overweight children. Ann Pediatr Endocrinol Metab 24:104–107. https://doi.org/10.6065/apem.2019.24.2.104
Amin S, El Amrousy D, Elrifaey S et al (2018) Serum osteocalcin levels in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 66:117–121. https://doi.org/10.1097/MPG.0000000000001768
Niimi H, Nishioka T, Kurayama H, Nakajima H (1988) Serum osteocalcin in normal children and children with glucocorticoid-induced osteoporosis. J Bone Miner Metab 6:38–42. https://doi.org/10.1007/BF02378738
Rosenquist C, Qvist P, Bjarnason N, Christiansen C (1995) Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439–1445. https://doi.org/10.1093/clinchem/41.10.1439
Takahashi M, Kushida K, Nagano A, Inoue T (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67–76. https://doi.org/10.1016/S0009-8981(99)00251-X
Nagasue K, Inaba M, Okuno S et al (2003) Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomed Pharmacother 57:98–104. https://doi.org/10.1016/S0753-3322(02)00344-X
Garnero P, Ferreras M, Karsdal MA et al (2003) The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. https://doi.org/10.1359/jbmr.2003.18.5.859
Risteli J, Elomaa I, Niemi S et al (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635–640. https://doi.org/10.1093/clinchem/39.4.635
Chubb SAP, Mandelt CD, Vasikaran SD (2015) Comparison of results from commercial assays for plasma CTX: the need for harmonization. Clin Biochem 48:519–524. https://doi.org/10.1016/j.clinbiochem.2015.03.002
Cavalier E, Eastell R, Jørgensen NR et al (2021) A multicenter study to evaluate harmonization of assays for C-terminal telopeptides of type I collagen (ß-CTX): a report from the IFCC-IOF committee for bone metabolism (C-BM). Calcif Tissue Int 108:785–797. https://doi.org/10.1007/s00223-021-00816-5
Herrmann D, Intemann T, Lauria F et al (2014) Reference values of bone stiffness index and C-terminal telopeptide in healthy European children. Int J Obes 38:S76-85. https://doi.org/10.1038/ijo.2014.138
Vincent A, Souberbielle JC, Brauner R (2018) Comparison of two bone markers with growth evolution in 74 girls with central precocious puberty. BMC Pediatr 18:224. https://doi.org/10.1186/s12887-018-1194-8
Monjardino T, Silva P, Amaro J et al (2019) Bone formation and resorption markers at 7 years of age: relations with growth and bone mineralization. PLoS ONE 14:e0219423. https://doi.org/10.1371/journal.pone.0219423
Thiering E, Brüske I, Kratzsch J et al (2015) Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. Sci Rep 5:18138. https://doi.org/10.1038/srep18138
Marwaha RK, Garg MK, Mithal A et al (2019) Effect of Vitamin D supplementation on bone turnover markers in children and adolescents from North India. Indian J Endocrinol Metab 23:27–34. https://doi.org/10.4103/ijem.IJEM_149_18
Radetti G, Franceschi R, Adami S et al (2014) Higher circulating parathormone is associated with smaller and weaker bones in obese children. Calcif Tissue Int 95:1–7. https://doi.org/10.1007/s00223-014-9853-8
Dimitri P, Wales JK, Bishop N (2011) Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone 48:189–196. https://doi.org/10.1016/j.bone.2010.09.034
Kurgan N, McKee K, Calleja M et al (2020) Cytokines, adipokines, and bone markers at rest and in response to plyometric exercise in obese vs normal weight adolescent females. Front Endocrinol. https://doi.org/10.3389/fendo.2020.531926
Qvist P, Christgau S, Pedersen BJ et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61. https://doi.org/10.1016/S8756-3282(02)00791-3
Mostafa YA, Meyer RA, Latorraca R (1982) A simple and rapid method for osteoclast identification using a histochemical method for acid phosphatase. Histochem J 14:409–413. https://doi.org/10.1007/BF01011853
Halleen JM, Tiitinen SL, Ylipahkala H et al (2006) Tartrate-resistant acid phosphates 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 52(9–10):499–509
Rissanen JP, Suominen MI, Peng Z, Halleen JM (2008) Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. https://doi.org/10.1007/s00223-007-9091-4
Mira-Pascual L, Patlaka C, Desai S et al (2020) A Novel Sandwich ELISA for tartrate-resistant acid phosphatase 5a and 5b protein reveals that both isoforms are secreted by differentiating osteoclasts and correlate to the type i collagen degradation marker CTX-I in vivo and in vitro. Calcif Tissue Int 106:194–207. https://doi.org/10.1007/s00223-019-00618-w
Halleen JM, Hentunen TA, Karp M et al (1998) Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res. https://doi.org/10.1359/jbmr.19126.96.36.1993
Cavalier E (2018) Bone markers and chronic kidney diseases. J Lab Precis Med 3:62. https://doi.org/10.21037/jlpm.2018.07.03
Shidara K, Inaba M, Okuno S et al (2008) Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 82:278–287. https://doi.org/10.1007/s00223-008-9127-4
Cavalier E, Eastell R, Jørgensen NR, et al (2018) Bone turnover markers. In: Encyclopedia of Endocrine Diseases. pp 4; 116–127
Chen CJ, Chao TY, Janckila AJ et al (2005) Evaluation of the activity of tartrate-resistant acid phosphatase isoform 5b in normal Chinese children—A novel marker for bone growth. J Pediatr Endocrinol Metab 18:55–62. https://doi.org/10.1515/JPEM.2005.18.1.55
Lau KHW, Onishi T, Wergedal JE et al (1987) Characterization and assay of tartrate-resistant acid phosphatase activity in serum: potential use to assess bone resorption. Clin Chem. https://doi.org/10.1093/clinchem/33.4.458
Scarnecchia L, Minisola S, Pacitti MT et al (1991) Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest. https://doi.org/10.3109/00365519109104560
Preussner R, Sauer-Eppel H, Oremek G (2014) Tartrate-resistant acid phosphatase 5b as a diagnostic marker of bone metastases in patients with renal cell carcinoma. Integr Cancer Sci Ther 1:35–38
Cavalier E, Lukas PDP (2021) Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2021-1190
Szulc P (2018) Bone turnover: biology and assessment tools. Best Pract. Res Clin Endocrinol Metab 32
Rauch F (2006) Watching bone cells at work: what we can see from bone biopsies. Pediatr Nephrol 21
Clark LC, Beck E (1950) Plasma “alkaline” phosphatase activity. I. Normative data for growing children. J Pediatr. https://doi.org/10.1016/S0022-3476(50)80103-8
Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone. https://doi.org/10.1016/S8756-3282(00)00269-6
Rauch F, Lalic L, Roughley P, Glorieux FH (2010) Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. https://doi.org/10.1359/jbmr.091109
Lund AM, Hansen M, Kollerup G et al (1998) Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr Int J Paediatr. https://doi.org/10.1111/j.1651-2227.1998.tb00920.x
Barber LA, Abbott C, Nakhate V et al (2019) Longitudinal growth curves for children with classical osteogenesis imperfecta (types III and IV) caused by structural pathogenic variants in type I collagen. Genet Med. https://doi.org/10.1038/s41436-018-0307-y
Wein MN, Kronenberg HM (2018) Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a031237
Baecker N, Tomic A, Mika C et al (2003) Bone resorption is induced on the second day of bed rest: results of a controlled crossover trial. J Appl Physiol. https://doi.org/10.1152/japplphysiol.00264.2003
Buehlmeier J, Frings-Meuthen P, Mohorko N, et al (2017) Markers of bone metabolism during 14 days of bed rest in young and older men. J Musculoskelet Neuronal Interact 17
Chotiyarnwong P, McCloskey E V. (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16
Hartmann K, Koenen M, Schauer S et al (2016) Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol Rev. https://doi.org/10.1152/physrev.00011.2015
Hyams JS, Moore RE, Leichtner AM et al (1988) Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr. https://doi.org/10.1016/S0022-3476(88)80210-5
Saarela T, Risteli J, Koivisto M (2003) Effects of short-term dexamethasone treatment on collagen synthesis and degradation markers in preterm infants with developing lung disease. Acta Paediatr Int J Paediatr. https://doi.org/10.1080/08035320310002687
Crofton PM, Shrivastava A, Wade JC et al (2000) Effects of dexamethasone treatment on bone and collagen turnover in preterm infants with chronic lung disease. Pediatr Res. https://doi.org/10.1203/00006450-200008000-00007
Vihinen MK, Kolho KL, Ashorn M et al (2008) Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol. https://doi.org/10.1530/EJE-08-0429
Söderpalm AC, Magnusson P, Åhlander AC et al (2007) Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy. Neuromuscul Disord. https://doi.org/10.1016/j.nmd.2007.05.008
Crowley S, Trivedi P, Risteli L et al (1998) Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr. https://doi.org/10.1016/S0022-3476(98)70011-3
Heuck C, Heickendorff L, Wolthers OD (2000) A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child. https://doi.org/10.1136/adc.83.4.334
Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49
Rauch F, Plotkin H, Travers R et al (2003) Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2002-021371
Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2010-0636
Palomo T, Fassier F, Ouellet J et al (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res. https://doi.org/10.1002/jbmr.2567
Rauch F, Munns C, Land C, Glorieux FH (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2005-2413
Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15
Hoyer-Kuhn H, Franklin J, Allo G, et al (2016) Safety and efficacy of denosumab in children with osteogenesis imperfecta - A first prospective trial. J Musculoskelet Neuronal Interact 16
Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18
Akel U, Robinson ME, Werier J et al (2019) Local tumor recurrence and escape from suppression of bone resorption with denosumab treatment in two adolescents with giant cell tumors of bone. JBMR Plus. https://doi.org/10.1002/jbm4.10196
Hartwell D, Riis BJ, Christiansen C (1990) Serum bone gla protein: a Potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab. https://doi.org/10.1210/jcem-71-1-122
Rauch F, Schnabel D, Seibel MJ et al (1995) Urinary excretion of galactosyl-hydroxylysine is a marker of growth in children. J Clin Endocrinol Metab. https://doi.org/10.1210/jcem.80.4.7714103
Andersson B, Swolin-Eide D, Magnusson P, Albertsson-Wikland K (2015) Short-term changes in bone formation markers following growth hormone (GH) treatment in short prepubertal children with a broad range of GH secretion. Clin Endocrinol. https://doi.org/10.1111/cen.12499
Swolin-Eide D, Andersson B, Hellgren G et al (2018) Variation of bone acquisition during growth hormone treatment in children can be explained by proteomic biomarkers, bone formation markers, body composition and nutritional factors. Bone. https://doi.org/10.1016/j.bone.2018.07.023
Schönau E, Westermann F, Rauch F et al (2001) A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol. https://doi.org/10.1530/eje.0.1440013
Rauch F, Georg M, Stabrey A et al (2002) Collagen markers deoxypyridinoline and hydroxylysine glycosides: pediatric reference data and use for growth prediction in growth hormone-deficient children. Clin Chem. https://doi.org/10.1093/clinchem/48.2.315
Crofton PM, Stirling HF, Schönau E, Kelnar CJH (1996) Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin Endocrinol. https://doi.org/10.1046/j.1365-2265.1996.706cn527.x
Vihervuori E, Turpeinen M, Siimes MA et al (1997) Collagen formation and degradation increase during growth hormone therapy in children. Bone. https://doi.org/10.1016/S8756-3282(96)00332-8
Gascoin-Lachambre G, Trivin C, Brauner R, Souberbielle JC (2007) Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: comparison of intrauterine growth retardation and idiopathic short stature. Growth Horm IGF Res. https://doi.org/10.1016/j.ghir.2007.01.008
Loftus J, Lindberg A, Aydin F, et al (2017) Individualised growth response optimisation (iGRO) tool: an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone. J Pediatr Endocrinol Metab 30
Baroncelli GI, Bertelloni S, Ceccarelli C et al (2000) Bone turnover in children with vitamin D deficiency rickets before and during treatment. Acta Paediatr Int J Paediatr. https://doi.org/10.1111/j.1651-2227.2000.tb00329.x
Rauch F, Middelmann B, Cagnoli M et al (1997) Comparison of total alkaline phosphatase and three assays for bone- specific alkaline phosphatase in childhood and adolescence. Acta Paediatr Int J Paediatr. https://doi.org/10.1111/j.1651-2227.1997.tb08938.x
de Castro MJ, de Lamas C, Sánchez-Pintos P, et al (2020) Bone status in patients with phenylketonuria: a systematic review. Nutrients 12
Kryskiewicz E, Pawlowska J, Pludowski P et al (2012) Bone metabolism in cholestatic children before and after living-related liver transplantation-a long-term prospective study. J Clin Densitom. https://doi.org/10.1016/j.jocd.2011.09.007
Branca F, Ferro-Luzzi A, Robins SP, Golden MHN (1992) Bone turnover in malnourished children. Lancet. https://doi.org/10.1016/0140-6736(92)92754-4
Klein GL, Herndon DN, Goodman WG et al (1995) Histomorphometric and biochemical characterization of bone following acute severe burns in children. Bone. https://doi.org/10.1016/8756-3282(95)00279-1
Pepmueller PH, Cassidy JT, Allen SH, Hillman LS (1996) Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum. https://doi.org/10.1002/art.1780390506
Halton JM, Atkinson SA, Fraher L et al (1996) Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res. https://doi.org/10.1002/jbmr.5650111122
Crofton PM, Ahmed SF, Wade JC et al (1998) Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.83.9.3121
Daly A, Högler W, Crabtree N et al (2021) A three-year longitudinal study comparing bone mass, density, and geometry measured by dxa, pqct, and bone turnover markers in children with pku taking l-amino acid or glycomacropeptide protein substitutes. Nutrients. https://doi.org/10.3390/nu13062075
Shen Y, Shiau S, Strehlau R et al (2021) Persistently lower bone mass and bone turnover among South African children living with well controlled HIV. AIDS. https://doi.org/10.1097/qad.0000000000002990
Steell L, Gray SR, Russell RK et al (2021) Pathogenesis of musculoskeletal deficits in children and adults with inflammatory bowel disease. Nutrients. https://doi.org/10.3390/nu13082899
Ward LM, Rauch F, Matzinger MA et al (2010) Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporos Int. https://doi.org/10.1007/s00198-009-0969-z
Ward LM, Ma J, Rauch F et al (2017) Musculoskeletal health in newly diagnosed children with Crohn’s disease. Osteoporos Int. https://doi.org/10.1007/s00198-017-4159-0
Thayu M, Leonard MB, Hyams JS et al (2008) Improvement in biomarkers of bone formation during infliximab therapy in pediatric crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2008.07.010
Sorva R, Kivivuori SM, Turpeinen M et al (1997) Very low rate of type I collagen synthesis and degradation in newly diagnosed children with acute lymphoblastic leukemia. Bone. https://doi.org/10.1016/S8756-3282(96)00343-2
Crofton PM, Ahmed SF, Wade JC et al (2000) Bone turnover and growth during and after continuing chemotherapy in children with acute lymphoblastic leukemia. Pediatr Res. https://doi.org/10.1203/00006450-200010000-00012
Crofton PM, Ahmed SF, Wade JC et al (1999) Effects of a third intensification block of chemotherapy on bone and collagen turnover, insulin-like growth factor I, its binding proteins and short-term growth in children with acute lymphoblastic leukaemia. Eur J Cancer. https://doi.org/10.1016/S0959-8049(99)00060-X
Delvin E, Alos N, Rauch F et al (2019) Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: a PETALE study. Clin Nutr. https://doi.org/10.1016/j.clnu.2018.02.006
Santos F, Díaz-Anadón L, Ordóñez FA, Haffner D (2021) Bone Disease in CKD in Children. Calcif Tissue Int 108
Swolin-Eide D, Hansson S, Magnusson P (2009) Children with chronic kidney disease: a 3-year prospective study of growth, bone mass and bone turnover. Acta Paediatr Int J Paediatr. https://doi.org/10.1111/j.1651-2227.2008.01073.x
Meza K, Biswas S, Zhu YS et al (2021) Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease. Pediatr Nephrol. https://doi.org/10.1007/s00467-020-04846-3
Swolin-Eide D, Hansson S, Magnusson P (2013) Skeletal effects and growth in children with chronic kidney disease: a 5-year prospective study. J Bone Miner Metab. https://doi.org/10.1007/s00774-012-0412-y
Swolin-Eide D, Hansson S, Magnusson P (2018) A 3-year longitudinal study of skeletal effects and growth in children after kidney transplantation. Pediatr Transplant. https://doi.org/10.1111/petr.13253
Ferrari S, Bianchi ML, Eisman JA, et al (2012) Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 23
Bhattoa HP, Cavalier E, Eastell R et al (2021) Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood. Clin Chim Acta. https://doi.org/10.1016/j.cca.2020.12.023
Wang X, Liu L, Li P et al (2017) Reference and influential factors of serum bone markers in chinese adolescents. Sci Rep. https://doi.org/10.1038/s41598-017-17670-x
Paldánius PM, Ivaska KK, Mäkitie O, Viljakainen H (2021) Serum and urinary osteocalcin in healthy 7- to 19-year-old finnish children and adolescents. Front Pediatr. https://doi.org/10.3389/fped.2021.610227
Choi JS, Park I, Lee SJ et al (2019) Serum procollagen type IN-terminal propeptide and osteocalcin levels in Korean children and adolescents. Yonsei Med J. https://doi.org/10.3349/ymj.2019.60.12.1174
Chailurkit LO, Suthutvoravut U, Mahachoklertwattana P et al (2005) Biochemical markers of bone formation in Thai children and adolescents. Endocr Res. https://doi.org/10.1080/07435800500371607
Callegari ET, Gorelik A, Garland SM et al (2017) Bone turnover marker reference intervals in young females. Ann Clin Biochem. https://doi.org/10.1177/0004563216665123
Alberti C, Chevenne D, Mercat I et al (2011) Serum concentrations of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3), IGF-1/IGFBP-3 ratio, and markers of bone turnover: reference values for French children and adolescents and z-score comparability with other references. Clin Chem. https://doi.org/10.1373/clinchem.2011.169466
Conflict of interest
Aurélie Ladang and Edgard Delvin declare no conflict of interest. Frank Rauch declare consulting or speaker fees for Novartic Inc, Ultragenyx Inc, and Sanofi Inc. Etienne Cavalier is consultant for IDS, DiaSorin, Fujirebio, Nittobo, bioMérieux, and Werfen.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ladang, A., Rauch, F., Delvin, E. et al. Bone Turnover Markers in Children: From Laboratory Challenges to Clinical Interpretation. Calcif Tissue Int 112, 218–232 (2023). https://doi.org/10.1007/s00223-022-00964-2
- Bone turnover markers